This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here. Hide this message

Laboratory Medicine

Test Directory / NT-Pro BNP

NT-Pro BNP

Brown clotted serum, gel barrier

TestNT-Pro BNP
Common AbbreviationsBNP
ProfileNA
Tube typeBrown clotted serum, gel barrier
Clinical IndicationDetermination of NT-proBNP levels in plasma can be useful in identifying patients with heart failure, assessing the severity, predicting increased morbidity and monitoring the therapeutic response. ProBNP, the amino acid precursor of BNP, is synthesised and released by ventricular myocytes in response to increased ventricular wall tension. ProBNP is cleaved to release the active hormone (BNP) and the N-terminal inactive peptide (NT-proBNP). BNP antagonizes the renin-angiotensin-aldosterone (RAAS) system by causing natriuresis, diuresis and vasodilation-inhibiting renin excretion and aldosterone production. Plasma levels of both BNP and NT-proBNP are markedly increased in subjects with left ventricular dysfunction. NT-proBNP has shown advantages over BNP as a biochemical marker because of its longer half-life, better in vitro stability, reduced intra-individual fluctuation and higher circulating concentration. BNP levels are also raised in conditions other than heart failure including critical illness, anaemia, stroke and pulmonary disease.
Specimen TypeBlood
Sample typePlasma
Minimum Volume0.5mL If requesting more than 10 tests please send an additional brown clotted serum sample.
Special PrecautionsNo special requirements
Stability 3 days at 20-250C, 6 days at 2-80C and 2 years at -200C
Turnaround TimeInpatient: 24 hours Outpatient/ GP: 24 hours
LaboratoryYork and Scarborough
Reference Interval<400 ng/L: Normal level - Heart failure unlikely 400 - 2000 ng/L: Raised level - Refer within 6 weeks if clinically appropriate >2000 ng/L: Very high level - Refer urgently if clinically appropriate Taken from NICE Clinical Guidance 108
Limitations Analysis should not be performed on haemolysed, icteric or lipaemic samples. The assay is unaffected by biotin < 123 nmol/L or < 30 ng/mL. No interference was observed from rheumatoid factors up to a concentration of 1500 IU/mL. No interference was observed from IgG < 6.0 g/dL; IgA < 1.6 g/dL; IgM < 1.0 g/dL Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found. In addition, special cardiac drugs were tested. No interference with the assay was found. In rare cases, interference due to extremely high titers of antibodies to analyte specific antibodies, streptavidin or ruthenium can occur.
Notes
DSC_5694

A-Z of Services

IMG_3571

Fundraising

Chinese Poland

View all languages >